09 September 2002
Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations
Marina Núńez, Carmen de Mendoza, Luisa Valer, Esperanza Casas, Soledad López-Calvo, Ángeles Castro, Beatriz Rosón, Daniel Podzamczer, Amalia Rubio, Juan Berenguer, Vincent SorianoMed Sci Monit 2002; 8(9): CR620-623 :: ID: 13277
Abstract
Summary
Background: The purpose of our study was to assess the presence of nelfinavir (NFV)-associated resistance mutations at the time of early virological failure in subjects receiving NFV as part of a first protease inhibitor (PI)-based triple regimen.
Material/Methods: Subjects failing their first PI-based NFV-containing triple regimen were identified in six Spanish hospitals. HIV genotyping was carried out in plasma samples collected at the time of
the first viral rebound.
Results: Upon initiation of NFV-based therapy, 19 of the 30 subjects (63%) were naïve; 11 (37%) had been exposed to nucleoside analogues. Median HIV-RNA at the time of viral rebound was 4,
180 copies/ml. PCR-amplified products were obtained in 22 subjects (73%). These products were sequenced and primary PI resistance mutations were recognized in 6 patients (27%). All six individuals harbored the D30N mutation, and none presented the L90M mutation. Other PI resistance mutations were present in 5 subjects (at codons 36, 63, 71, 77, 82 and/or 88). Secondary PI resistance mutations were present in another 9 subjects. By contrast, mutations conferring resistance to reverse transcriptase inhibitors were present in 50% of the patients, and the M184V substitution was the most frequently seen.
Conclusions: Nearly 75% of patients failing their first PI-based triple regimen containing NFV do not harbor PI resistance mutations. The D30N substitution, rather than L90M, is the most frequently
recognized, which does not challenge the efficacy of further rescue interventions with other PIs. This observation supports the use of nelfinavir as first protease inhibitor
Keywords: Drug Resistance, Genes, Viral, Genotype, HIV - genetics, HIV Protease - genetics, HIV Protease Inhibitors - therapeutic use, HIV Seropositivity - drug therapy, HIV-1 Reverse Transcriptase - genetics, Mutation, Nelfinavir - therapeutic use
Editorial
01 November 2024 : Editorial
Editorial: Artificial Intelligence (AI), Digital Image Analysis, and the Future of Cancer Diagnosis and PrognosisDOI: 10.12659/MSM.947038
Med Sci Monit 2024; 30:e947038
In Press
Clinical Research
Comprehensive Analysis of Immune Infiltration and Key Genes in Peri-Implantitis Using Bioinformatics and Mo...Med Sci Monit In Press; DOI: 10.12659/MSM.941870
Clinical Research
High-Resolution Anorectal Manometry and Balloon Expulsion Test Outcomes in Functional Constipation: A Compa...Med Sci Monit In Press; DOI: 10.12659/MSM.944599
Clinical Research
Plaque Removal and Gingival Bleeding Using Biodegradable Toothbrushes: Salvadora persica, Bamboo, and Nylo...Med Sci Monit In Press; DOI: 10.12659/MSM.944469
Clinical Research
Comparative Analysis of Extended Curettage with Plate Fixation and Extended Curettage with Intramedullary N...Med Sci Monit In Press; DOI: 10.12659/MSM.945157
Most Viewed Current Articles
17 Jan 2024 : Review article 6,190,650
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research 1,908,656
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 695,192
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
07 Jan 2022 : Meta-Analysis 260,387
Efficacy and Safety of Light Therapy as a Home Treatment for Motor and Non-Motor Symptoms of Parkinson Dise...DOI :10.12659/MSM.935074
Med Sci Monit 2022; 28:e935074